Search Results for: EGFR

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
NTRK2 neurotrophic receptor tyrosine kinase 2
  • NGF-independant TRKA activation
  • BDNF activates NTRK2 (TRKB) signaling
  • NTF3 activates NTRK2 (TRKB) signaling
  • NTF4 activates NTRK2 (TRKB) signaling
  • Activated NTRK2 signals through RAS
  • Activated NTRK2 signals through PLCG1
  • Activated NTRK2 signals through PLCG1
  • Activated NTRK2 signals through PI3K
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FYN
  • NTRK2 activates RAC1
  • NTRK2 activates RAC1
  • Activated NTRK2 signals through CDK5
  • Amitriptyline
  • Esketamine
  • Entrectinib
  • Fostamatinib
  • Larotrectinib
  • Neuroblastoma
NUMB NUMB endocytic adaptor protein
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Recycling pathway of L1
  • Degradation of GLI1 by the proteasome
  • Hedgehog 'on' state
NUMBL NUMB like endocytic adaptor protein
OAZ1 ornithine decarboxylase antizyme 1
  • Regulation of ornithine decarboxylase (ODC)
  • Ornithine
OLFM1 olfactomedin 1
PAK1 p21 (RAC1) activated kinase 1
  • Generation of second messenger molecules
  • Regulation of actin dynamics for phagocytic cup formation
  • FCERI mediated MAPK activation
  • FCERI mediated MAPK activation
  • DSCAM interactions
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • Sema3A PAK dependent Axon repulsion
  • Activation of RAC1
  • Signal transduction by L1
  • Smooth Muscle Contraction
  • VEGFR2 mediated vascular permeability
  • CD209 (DC-SIGN) signaling
  • RHO GTPases activate PKNs
  • RHO GTPases Activate ROCKs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • MAPK6/MAPK4 signaling
  • G beta:gamma signalling through CDC42
  • Fostamatinib
PCNA proliferating cell nuclear antigen
  • Translesion synthesis by REV1
  • Recognition of DNA damage by PCNA-containing replication complex
  • Translesion Synthesis by POLH
  • Transcription of E2F targets under negative control by DREAM complex
  • Polymerase switching on the C-strand of the telomere
  • Processive synthesis on the C-strand of the telomere
  • Telomere C-strand (Lagging Strand) Synthesis
  • Removal of the Flap Intermediate from the C-strand
  • SUMOylation of DNA replication proteins
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • PCNA-Dependent Long Patch Base Excision Repair
  • Translesion synthesis by POLK
  • Translesion synthesis by POLI
  • Termination of translesion DNA synthesis
  • HDR through Homologous Recombination (HRR)
  • Gap-filling DNA repair synthesis and ligation in GG-NER
  • Dual Incision in GG-NER
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Polymerase switching
  • Removal of the Flap Intermediate
  • Processive synthesis on the lagging strand
  • G1/S-Specific Transcription
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Liothyronine
  • Acetylsalicylic acid
PDCD6IP programmed cell death 6 interacting protein
  • Budding and maturation of HIV virion
  • Uptake and function of anthrax toxins
  • RIPK1-mediated regulated necrosis
  • Regulation of necroptotic cell death
PDGFRA platelet derived growth factor receptor alpha
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Imatinib-resistant PDGFR mutants
  • Sunitinib-resistant PDGFR mutants
  • Regorafenib-resistant PDGFR mutants
  • Sorafenib-resistant PDGFR mutants
  • PDGFR mutants bind TKIs
  • Becaplermin
  • Imatinib
  • Sunitinib
  • XL820
  • Olaratumab
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Ripretinib
  • Glioma
PDGFRB platelet derived growth factor receptor beta
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Becaplermin
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • XL999
  • XL820
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Nintedanib
  • Polaprezinc
  • Trapidil
  • Foreskin fibroblast (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Pexidartinib
  • Ripretinib
  • Pralsetinib
  • Glioma
PDK3 pyruvate dehydrogenase kinase 3
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Signaling by Retinoic Acid
  • Radicicol
  • Dihydrolipoic Acid
PDP1 pyruvate dehydrogenase phosphatase catalytic subunit 1
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Pyruvate dehydrogenase complex deficiency; X-linked Leigh syndrome
PFKP phosphofructokinase, platelet
  • Glycolysis
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of PIPs at the Golgi membrane
  • Synthesis of PIPs at the early endosome membrane
  • Synthesis of PIPs at the late endosome membrane
  • Golgi Associated Vesicle Biogenesis
  • Clathrin-mediated endocytosis
PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta
  • Synthesis of PIPs at the plasma membrane
  • Fostamatinib
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • ATP
  • Caffeine
  • XL765
  • Wortmannin
  • Pilaralisib
  • Alpelisib
  • Copanlisib
  • Ovarian cancer
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Isoprenaline
  • SF1126
  • Enzastaurin
  • Wortmannin
PIK3R2 phosphoinositide-3-kinase regulatory subunit 2
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • Downstream signal transduction
  • Rho GTPase cycle
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Isoprenaline
  • SF1126
PIK3R3 phosphoinositide-3-kinase regulatory subunit 3
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Isoprenaline
  • SF1126
PIM1 Pim-1 proto-oncogene, serine/threonine kinase
  • Interleukin-4 and Interleukin-13 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • 3,4-Dihydroxy-1-Methylquinolin-2(1h)-One
  • Staurosporine
  • LY-294002
  • Imidazole
  • (3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One
  • Bisindolylmaleimide I
  • Quercetin
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Dexfosfoserine
  • S,S-(2-Hydroxyethyl)Thiocysteine
  • IMIDAZOPYRIDAZIN 1
  • 4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one
  • (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile
  • N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine
  • (2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile
  • (4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile
  • Tricetin
  • 6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE
  • 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine
  • N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine
  • 2,3-diphenyl-1H-indole-7-carboxylic acid
  • Fostamatinib

Page 12 out of 21 pages